RecruitingPhase 2NCT06604520
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Studying Behavioral variant of frontotemporal dementia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Christopher Morrow, MDJohns Hopkins University
- Intervention
- Vortioxetine(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 45 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- The Johns Hopkins Hospital, Baltimore, Maryland, United States
Collaborators
National Institute on Aging (NIA) · Lundbeck LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06604520 on ClinicalTrials.govOther trials for Behavioral variant of frontotemporal dementia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07531732Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative DiseasesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT05742698Nabilone for Agitation in Frontotemporal DementiaSimon Ducharme, MD
- RECRUITINGNANCT06706687A Study of the Behavioral Variant of Frontotemporal Dementia and Bipolar Disorder: a Neuroimaging and Epigenetics Integrated ApproachFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- ENROLLING BY INVITATIONNCT04680130Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related DisordersMayo Clinic
See all trials for Behavioral variant of frontotemporal dementia →